These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36651339)

  • 41. Polymer-Free vs. Polymer-Coated Drug-Eluting Stents for the Treatment of Coronary Artery Disease: A Meta-Analysis of 16 Randomized Trials.
    Verdoia M; Kedhi E; Suryapranata H; Galasso G; Dudek D; De Luca G
    Cardiovasc Revasc Med; 2020 Jun; 21(6):745-753. PubMed ID: 31669109
    [TBL] [Abstract][Full Text] [Related]  

  • 42. One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in diabetic patients: Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry).
    Beneduce A; Ferrante G; Ielasi A; Pivato CA; Chiarito M; Cappelletti A; Baldetti L; Magni V; Prati E; Falcone S; Pierri A; De Martini S; Montorfano M; Parisi R; Rutigliano D; Locuratolo N; Anzuini A; Tespili M; Margonato A; Benassi A; Briguori C; Reimers B; Fabbiocchi F; Bartorelli A; Colombo A; Godino C
    Catheter Cardiovasc Interv; 2020 Aug; 96(2):255-265. PubMed ID: 31905259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rationale and study design of the RESERVOIR trial: a randomized trial comparing reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus.
    Romaguera R; Brugaletta S; Gomez-Lara J; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Gómez-Hospital JA; Montanya E; Alfonso F; Valgimigli M; Sabate M; Cequier A
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):E116-22. PubMed ID: 25380051
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of diabetes on clinical outcomes after revascularization with sirolimus-eluting and biolimus-eluting stents with biodegradable polymer from the SORT OUT VII trial.
    Ellert J; Christiansen EH; Maeng M; Raungaard B; Jensen SE; Kristensen SD; Veien KT; Junker AB; Jakobsen L; Aarøe J; Terkelsen CJ; Kahlert J; Villadsen AB; Bøtker HE; Jensen LO
    Catheter Cardiovasc Interv; 2019 Mar; 93(4):567-573. PubMed ID: 30244533
    [TBL] [Abstract][Full Text] [Related]  

  • 45. One-year clinical outcome of amphilimus polymer-free drug-eluting stent in diabetes mellitus patients: Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTre rEgistry).
    Colombo A; Godino C; Donahue M; Testa L; Chiarito M; Pavon AG; Colantonio R; Cappelletti A; Monello A; Magni V; Milazzo D; Parisi R; Nicolino A; Moshiri S; Fattori R; Aprigliano G; Palloshi A; Caramanno G; Montorfano M; Bedogni F; Margonato A; Briguori C
    Int J Cardiol; 2016 Jul; 214():113-20. PubMed ID: 27060269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen), a randomized, controlled, noninferiority trial.
    Park KW; Kang SH; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Hur SH; Ryu JK; Lee BR; Park YW; Chae IH; Kim HS;
    J Am Coll Cardiol; 2014 Jul; 63(25 Pt A):2805-16. PubMed ID: 24814486
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents.
    Kereiakes DJ; Windecker S; Jobe RL; Mehta SR; Sarembock IJ; Feldman RL; Stein B; Dubois C; Grady T; Saito S; Kimura T; Underwood P; Allocco DJ; Meredith IT
    Circ Cardiovasc Interv; 2019 Sep; 12(9):e008152. PubMed ID: 31451014
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: Results from the Korea Acute Myocardial infarction Registry (KAMIR).
    Kim Y; Oh SS; Jeong MH; Ahn Y; Kim JH; Hong YJ; Sim DS; Kim MC; Kim HS; Yun KH; Oh SK; Kim CJ; Cho MC
    Cardiol J; 2019; 26(5):469-476. PubMed ID: 29745969
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
    Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L
    JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Leon MB; Kandzari DE; Eisenstein EL; Anstrom KJ; Mauri L; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; Kirtane AJ; McLaurin BT; Solomon SL; Douglas JS; Popma JJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1208-18. PubMed ID: 20129547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials.
    Ploumen EH; Buiten RA; Kok MM; Doggen CJM; Roguin A; Jessurun GAJ; Schotborgh CE; Danse PW; Benit E; Aminian A; van Houwelingen KG; Stoel MG; Scholte M; Hartmann M; Linssen GCM; Zocca P; von Birgelen C
    Int J Cardiol; 2021 Feb; 325():37-44. PubMed ID: 33148427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Three-year follow up of biodegradable polymer cobalt-chromium sirolimus-eluting stent (EXCROSSAL) in treating de novo coronary artery disease: Pooled analysis of CREDIT II and CREDIT III trials.
    Wang G; Ma G; Tao L; Yuan Z; Liu H; Hu X; Tong Q; Yu Z; Zhou X; Han Y
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():565-571. PubMed ID: 31944543
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Final 5-Year Report of the Randomized BIO-RESORT Trial Comparing 3 Contemporary Drug-Eluting Stents in All-Comers.
    Ploumen EH; Pinxterhuis TH; Buiten RA; Zocca P; Danse PW; Schotborgh CE; Scholte M; Gin RMTJ; Somi S; van Houwelingen KG; Stoel MG; de Man HAF; Hartmann M; Linssen GCM; van der Heijden LC; Kok MM; Doggen CJM; von Birgelen C
    J Am Heart Assoc; 2022 Nov; 11(22):e026041. PubMed ID: 36346050
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Three contemporary thin-strut drug-eluting stents implanted in severely calcified coronary lesions of participants in a randomized all-comers trial.
    Buiten RA; Ploumen EH; Zocca P; Doggen CJM; van Houwelingen KG; Danse PW; Schotborgh CE; Stoel MG; Scholte M; Linssen GCM; de Man FHAF; von Birgelen C
    Catheter Cardiovasc Interv; 2020 Nov; 96(5):E508-E515. PubMed ID: 32237060
    [TBL] [Abstract][Full Text] [Related]  

  • 57. One-year clinical results of the NANO registry: A multicenter, prospective all-comers registry study in patients receiving implantation of a polymer-free sirolimus-eluting stent.
    Liu Y; Zhang Y; Li Y; Qi T; Pan D; Wang H; Liu C; Ma D; Fang Z; Zhang R; Mou F; Tao L;
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():658-664. PubMed ID: 31961057
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
    Cassese S; Kufner S; Xhepa E; Byrne RA; Kreutzer J; Ibrahim T; Tiroch K; Valgimigli M; Tölg R; Fusaro M; Schunkert H; Laugwitz KL; Mehilli J; Kastrati A
    Clin Res Cardiol; 2016 Jul; 105(7):575-84. PubMed ID: 26689707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial.
    Iqbal J; Serruys PW; Silber S; Kelbaek H; Richardt G; Morel MA; Negoita M; Buszman PE; Windecker S
    Circ Cardiovasc Interv; 2015 Jun; 8(6):e002230. PubMed ID: 26047993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.